ArriVent BioPharma, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:AVBP) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 215.5 M269.51 M326.56 M333.17 M349.3 M394.72 M Total liabilities 12.95 M19.64 M21.56 M25.95 M25.32 M27.88 M Total equity 202.54 M249.87 M305 M307.22 M323.98 M366.84 M Total liabilities & shareholders' equities 215.5 M269.51 M326.56 M333.17 M349.3 M394.72 M Total debt —————— Net debt ——————

News

ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case (NASDAQ:AVBP)

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case

ArriVent BioPharma: A First Assessment (NASDAQ:AVBP)

Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice

Are Medical Stocks Lagging AstraZeneca (AZN) This Year?

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP)

BTIG initiates ArriVent stock coverage with buy rating on oncology pipeline

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?

ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald